2. Immunology/Inflammation
  3. Interleukin Related
  4. Mycophenolate mofetil hydrochloride

Mycophenolate mofetil hydrochloride  (Synonyms: RS 61443 hydrochloride; TM-MMF hydrochloride)

Cat. No.: HY-B0199A Purity: 99.17%
COA
SDS
Handling Instructions Technical Support

Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection).

For research use only. We do not sell to patients.

CAS No. : 116680-01-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 12 publication(s) in Google Scholar

Other Forms of Mycophenolate mofetil hydrochloride:

Mycophenolate mofetil hydrochloride Related Antibodies

Top Publications Citing Use of Products

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):835-853.

    To investigate the effects of immunosuppressants on PBMCs, peripheral blood mononuclear cells from healthy volunteers were exposed to Mycophenolate Mofetil (15 µg/mL, 3 days).

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):835-853.

    The cytolytic activity of NK cells on K562 and HL60 cells. NK cells sorted by MACS were exposed to TAC, CSA, Mycophenolate Mofetil (15 µg/mL, 3 days), EVE, SIR, and CS and cultured for 3 d as effector cells.

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523.  [Abstract]

    The morphology of Mycophenolate Mofetil-LA@DSPE-PEG and Mycophenolate Mofetil-LA@PEG-PLA characterized by transmission electron microscopy (TEM).

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523.  [Abstract]

    The diameters and zeta potentials of Mycophenolate Mofetil-LA@DSPE-PEG and Mycophenolate Mofetil-LA@PEG-PLA characterized by Dynamic light scattering (DLS).

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523.  [Abstract]

    Cell viabilities of Huh7 cells, SUN‐449 cells, LM3 cells and Hep1‐6 cells treated with free Mycophenolate Mofetil, Mycophenolate Mofetil‐LA@DSPE‐PEG and Mycophenolate Mofetil‐LA@PEG‐PLA for 48 h.

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523.  [Abstract]

    Cell cycles determined by flow cytometry. Cells were treated with free Mycophenolate Mofetil (2 µg/mL) or Mycophenolate Mofetil-LA NPs (at 2 µg/mL Mycophenolate Mofetil-equivalent dose) for 48 h.

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523.  [Abstract]

    Colony Formation of Hep1-6 cells, SUN-449 cells and Huh7 cells. Hep1-6 cells, SUN-449 cells and Huh7 cells were treated with drugs at 0.5, 2 and 4 µg/mL (Mycophenolate Mofetil-equivalent concentration), respectively, for 96 h.

    Mycophenolate mofetil hydrochloride purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Apr;25(7):3511-3523.  [Abstract]

    Images of Hep1‐6 tumours after treatment with drugs at 20 mg/kg (Mycophenolate Mofetil‐equivalent concentration). Mice were orally administrated with free MMF (20 mg/kg) or intravenously injected with MMF‐LA NPs (at 20 mg/kg MMF‐equivalent dose) every other day for four times.

    View All Interleukin Related Isoform Specific Products:

    View All Isoforms
    IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection)[1][2].

    IC50 & Target

    IL-2

     

    In Vitro

    Mycophenolate mofetil hydrochloride (0-10 μg/mL; 1-3 d) significantly inhibits the in vitro proliferation of primary DA rat aortic smooth muscle cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Mycophenolate mofetil hydrochloride Related Antibodies

    Cell Proliferation Assay[1]

    Cell Line: DA rat aortic smooth muscle cells
    Concentration: 0-10 μg/mL
    Incubation Time: 1-3 days
    Result: Significantly inhibited the in vitro proliferation of primary DA rat aortic smooth muscle cells.
    This effect reversed after terminating incubation by medium change.
    In Vivo

    Mycophenolate mofetil hydrochloride (20 mg/kg/day; oral administration; once daily; from the day of transplantation to the day of sacrifice) significantly inhibits the histopathological manifestations of allograft arteriosclerosis in rat aortic allografts for up to 6 months by alleviating adventitial inflammation, medial necrosis, intimal thickening, and the proliferation of inflammatory cells and SMC[1].
    Mycophenolate mofetil hydrochloride (40 mg/kg/day; intraperitoneal injection; daily; 14 days post-injury) reduces intimal thickening and cell density in rats after carotid artery endothelial denudation, but its effect is not statistically significant[1].
    Mycophenolate mofetil hydrochloride (30 mg/kg/day; intragastric administration; once daily for 14 consecutive days) significantly delays the rejection response of hamster-to-rat limb xenotransplantation, with an average rejection time of 10.0 days[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Lewis rats (recipient); Golden Syrian hamsters (donor)[2]
    Dosage: 30 mg/kg/day
    Administration: i.g.; daily; 14 days (starting postoperative day 1)
    Result: Increased mean rejection time to 10.0 days.
    Achieved a 60% survival rate.
    Showed histologic grading of skin biopsies with 1 sample no rejection (R0), 3 samples lymphocytic infiltration (R1), 1 sample lymphocytic and neutrophilic infiltration (R2).
    Showed histologic grading of muscle biopsies with 1 sample lymphocytic and neutrophilic infiltration (R2), 6 samples mixed cell infiltration (R3).
    Molecular Weight

    469.96

    Formula

    C23H32ClNO7
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC.Cl
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    DMSO : 200 mg/mL (425.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1278 mL 10.6392 mL 21.2784 mL
    5 mM 0.4256 mL 2.1278 mL 4.2557 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (10.64 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (10.64 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1278 mL 10.6392 mL 21.2784 mL 53.1960 mL
    5 mM 0.4256 mL 2.1278 mL 4.2557 mL 10.6392 mL
    10 mM 0.2128 mL 1.0639 mL 2.1278 mL 5.3196 mL
    15 mM 0.1419 mL 0.7093 mL 1.4186 mL 3.5464 mL
    20 mM 0.1064 mL 0.5320 mL 1.0639 mL 2.6598 mL
    25 mM 0.0851 mL 0.4256 mL 0.8511 mL 2.1278 mL
    30 mM 0.0709 mL 0.3546 mL 0.7093 mL 1.7732 mL
    40 mM 0.0532 mL 0.2660 mL 0.5320 mL 1.3299 mL
    50 mM 0.0426 mL 0.2128 mL 0.4256 mL 1.0639 mL
    60 mM 0.0355 mL 0.1773 mL 0.3546 mL 0.8866 mL
    80 mM 0.0266 mL 0.1330 mL 0.2660 mL 0.6650 mL
    100 mM 0.0213 mL 0.1064 mL 0.2128 mL 0.5320 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Mycophenolate mofetil hydrochloride Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Mycophenolate mofetil116680-01-4RS 61443TM-MMFRS61443RS-61443Interleukin RelatedILB lymphocytesrat aortic allograftsnatural antibodieshamster-to-rat vascularized hindlimb xenograftinflammatory cellsinterleukin-2 receptorallograft arteriosclerosisT lymphocytessmooth muscle cellssmooth muscle α-actinInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Mycophenolate mofetil hydrochloride
    Cat. No.:
    HY-B0199A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.